Bank CEOs meet with Trump to discuss Fannie Mae and Freddie Mac - Bloomberg
Investing.com - Merck&Co (NYSE: MRK) reported fourth quarter EPS of $1.72, $0.09 worse than the analyst estimate of $1.81. Revenue for the quarter came in at $15.6B versus the consensus estimate of $15.47B.
Guidance
Merck&Co sees FY 2025 EPS of $8.88-$9.03 versus the analyst consensus of $9.21.
Merck&Co sees FY 2025 revenue of $64.10B-$65.60B versus the analyst consensus of $67.36B.
Merck&Co’s stock price closed at $99.79. It is down -1.36% in the last 3 months and down -20.91% in the last 12 months.
Merck&Co saw 0 positive EPS revisions and 13 negative EPS revisions in the last 90 days. See Merck&Co’s stock price’s past reactions to earnings here.
According to InvestingPro, Merck&Co’s Financial Health score is "great performance".
Check out Merck&Co’s recent earnings performance, and Merck&Co’s financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar